FDA approves new pancreatic cancer drug shown to extend survival

The FDA has approved Rasonque, a new drug by Revolution Medicines that extends median survival for metastatic pancreatic adenocarcinoma patients from under 6 to over 13 months, offering a significant new treatment option.

This Wire brief sits within Fusion42's coverage of Biotech, and 20 sources have reported it.